Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Accrued Expenses

12 Months Ended

Dec. 31, 2018

Accrued expenses and other current liabilities consisted of the following (in thousands):



	Years Ended December 31,
	2018		2017
Accrued license obligations	$	2,523	$	806
Compensation expense	2,380		2,325
Research and development fees	1,945		791
Professional fees	943		516
Audit and tax fees	378		424
Other current liabilities	945		1,308
Total	$	9,114	$	6,170